Soligenix, Inc. SNGX
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Soligenix, Inc. (SNGX) is a healthcare company listed in the US with a market value of about $8M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -171%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.
About Soligenix
Soligenix is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $7M in 2014 to $119371 in 2024, a decline of about 33.5% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 2791% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $119371 | $839359 | $948911 | $824268 | $2M | $5M | $5M | $5M | $10M |
| Net income | -$11M | -$8M | -$6M | -$14M | -$13M | -$18M | -$9M | -$9M | -$7M | -$3M |
| Free cash flow | -$10M | — | — | — | — | — | — | — | — | — |
| EPS (diluted) | $-2.14 | $-4.98 | $-12.66 | $-76.94 | $-75.02 | $-153.56 | $-115.17 | $-163.16 | $-278.33 | $-321.52 |
| Net margin | — | -6925.1% | -731.6% | -1454.1% | -1522.7% | -749.7% | -202.1% | -169.8% | -131.6% | -31.1% |
| ROIC | -200.5% | -212.6% | -158.7% | — | -113.2% | -124.2% | -630.0% | -109.8% | -43.4% | -27.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Soligenix stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Soligenix pay a dividend?
Not currently.
Is Soligenix a good stock to buy?
We do not give buy or sell advice. Soligenix scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.